Sanofi-aventis’s  anticoagulant Clexane® (enoxaparin sodium injection) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the prevention of venous thromboembolism (VTE) in patients undergoing orthopaedic surgery of the lower limbs such as total hip replacement, total knee replacement and hip fracture surgery.

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions. Venous thromboembolism is a frequent and preventable complication among patients hospitalized for orthopaedic surgery. Deep vein thrombosis (DVT) and pulmonary embolism are common manifestations of VTE and can significantly impact morbidity and mortality in surgical patients. The Japanese VTE guidelines state that, without prophylaxis, between 27% and 50% of orthopaedic surgery patients may suffer from deep vein thrombosis. Among the hospitalised patients at risk for VTE, 64% are those undergoing surgery(1).

Outside Japan with over 200 million patients treated in more than 100 countries, Clexane® / Lovenox® (enoxaparin sodium) is the most extensively studied and most widely used low-molecular-weight heparin in the world. In venous thrombosis, Clexane® / Lovenox® is recommended by international guidelines not only in orthopaedic and general surgical patients at high and moderate risk of VTE, but also for acutely ill medical patients, and is an important treatment option for millions of patients at risk of VTE(2). In arterial thrombosis, Clexane® / Lovenox® has demonstrated its effectiveness in preventing, in conjunction with other treatments, the ischaemic complications of unstable angina and myocardial infarction and is also recommended by international guidelines(2).